UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 3, 2007
--------------
ENZO BIOCHEM, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
NEW YORK
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
001-09974 13-2866202
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
527 MADISON AVENUE
NEW YORK, NEW YORK 10022
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(212) 583-0100
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS.
------------
On May 3, 2007, the Company issued a press release announcing that its wholly
owned subsidiary Enzo Life Sciences and Abbott have entered into an agreement
covering the supply of certain of Enzo's product to Abbott Molecular for use in
their FISH product line. The companies have also entered into a limited
non-exclusive royalty bearing cross-licensing agreement of patents for
fluorescence in situ hybridization ("FISH") systems, comparative genomic
hybridization ("CGH") analysis and labeling and detection technologies. The
press release issued by the Company announcing the foregoing is included as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
in its entirety into this Item 8.01.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
---------------------------------
(c) Exhibits.
--------
Exhibit No. Description
----------- -----------
99.1 Press Release of Enzo Biochem, Inc., dated May 3, 2007,
announcing agreements with Abbott
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ENZO BIOCHEM, INC.
Date: May 3, 2007 By: /s/ Barry Weiner
----------------------------------------
Barry Weiner
President and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press Release of Enzo Biochem, Inc., dated May 3, 2007,
announcing agreements with Abbott